By week 9 , significantly ( p < 0.01 ) greater proportions of patients receiving LDX than ATX met the response criteria of a reduction from baseline in ADHD-RS-IV total score of at least 25 % ( 90.5 vs. 76.7 % ) , 30 % ( 88.1 vs. 73.7 % ) or 50 % ( 73.0 vs. 50.4 % ) .